JP2017523784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523784A5 JP2017523784A5 JP2017505792A JP2017505792A JP2017523784A5 JP 2017523784 A5 JP2017523784 A5 JP 2017523784A5 JP 2017505792 A JP2017505792 A JP 2017505792A JP 2017505792 A JP2017505792 A JP 2017505792A JP 2017523784 A5 JP2017523784 A5 JP 2017523784A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence shown
- amino acid
- acid sequence
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033045P | 2014-08-04 | 2014-08-04 | |
| US62/033,045 | 2014-08-04 | ||
| US201562164783P | 2015-05-21 | 2015-05-21 | |
| US62/164,783 | 2015-05-21 | ||
| PCT/US2015/042986 WO2016022400A1 (en) | 2014-08-04 | 2015-07-30 | T cell immunotherapy specific for wt-1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018142600A Division JP2018183175A (ja) | 2014-08-04 | 2018-07-30 | Ｗｔ−１に特異的なｔ細胞免疫治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523784A JP2017523784A (ja) | 2017-08-24 |
| JP2017523784A5 true JP2017523784A5 (enExample) | 2018-09-06 |
| JP6712261B2 JP6712261B2 (ja) | 2020-06-24 |
Family
ID=53901124
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505792A Expired - Fee Related JP6712261B2 (ja) | 2014-08-04 | 2015-07-30 | Ｗｔ−１に特異的なｔ細胞免疫治療 |
| JP2018142600A Pending JP2018183175A (ja) | 2014-08-04 | 2018-07-30 | Ｗｔ−１に特異的なｔ細胞免疫治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018142600A Pending JP2018183175A (ja) | 2014-08-04 | 2018-07-30 | Ｗｔ−１に特異的なｔ細胞免疫治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10538572B2 (enExample) |
| EP (1) | EP3177314B1 (enExample) |
| JP (2) | JP6712261B2 (enExample) |
| CN (1) | CN107074970B (enExample) |
| CA (1) | CA2956545A1 (enExample) |
| ES (1) | ES2841274T3 (enExample) |
| WO (1) | WO2016022400A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014352834B2 (en) | 2013-11-22 | 2019-08-29 | Fred Hutchinson Cancer Research Center | Engineered high-affinity human T cell receptors |
| ES2979088T3 (es) | 2015-03-05 | 2024-09-24 | Fred Hutchinson Cancer Center | Proteínas de fusión inmunomoduladoras y usos de las mismas |
| US10975436B2 (en) | 2016-01-05 | 2021-04-13 | Diamir, Llc | Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders |
| ES2914648T3 (es) | 2016-04-08 | 2022-06-15 | Immunocore Ltd | Receptores de células T |
| US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| US11332713B2 (en) | 2016-11-16 | 2022-05-17 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| WO2018102795A2 (en) * | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| CA3049244A1 (en) | 2017-01-05 | 2018-07-12 | Fred Hutchinson Cancer Research Center | Systems and methods to improve vaccine efficacy |
| WO2018143454A1 (ja) * | 2017-02-06 | 2018-08-09 | 国立研究開発法人国立がん研究センター | 新規ｔ細胞受容体 |
| JP7037577B2 (ja) * | 2017-03-15 | 2022-03-16 | フレッド ハッチンソン キャンサー リサーチ センター | 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用 |
| US11725210B2 (en) | 2017-03-17 | 2023-08-15 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| EA201992536A1 (ru) | 2017-04-24 | 2020-03-05 | Оспедале Сан Раффаэле С.Р.Л. | Tcr и пептиды |
| ES2972783T3 (es) * | 2017-06-30 | 2024-06-17 | Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum | Tratamiento de las neoplasias malignas hematológicas |
| NL2019156B1 (en) * | 2017-06-30 | 2019-01-10 | Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum | Treatment of haematological malignancies |
| CN107267463A (zh) * | 2017-08-23 | 2017-10-20 | 安徽惠恩生物科技股份有限公司 | 一种针对乳腺癌的Car‑NK细胞制备方法 |
| WO2019058253A1 (en) | 2017-09-19 | 2019-03-28 | Tropic Biosciences UK Limited | MODIFICATION OF THE SPECIFICITY OF NON-CODING RNA MOLECULES FOR SILENCING GENE EXPRESSION IN EUKARYOTIC CELLS |
| CN111954679A (zh) | 2017-10-03 | 2020-11-17 | 朱诺治疗学股份有限公司 | Hpv特异性结合分子 |
| CN109777778B (zh) * | 2017-11-14 | 2023-07-18 | 中国科学院广州生物医药与健康研究院 | 一种基因改造的γδT细胞 |
| EP3728317A2 (en) | 2017-12-21 | 2020-10-28 | F. Hoffmann-La Roche AG | Antibodies binding to hla-a2/wt1 |
| DE112019000348B4 (de) | 2018-01-05 | 2021-10-28 | Nantbio, Inc. | Umprogrammierte t-zellen ähnliche nk-zellen |
| JP7355742B2 (ja) | 2018-01-18 | 2023-10-03 | フレッド ハッチンソン キャンサー センター | 細胞活性状態を調節することにより免疫細胞の炎症状態をインビボで変更すること |
| AU2019236204B2 (en) | 2018-03-15 | 2026-02-26 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| JP2021518160A (ja) | 2018-03-15 | 2021-08-02 | ケーエスキュー セラピューティクス， インコーポレイテッド | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| TWI840351B (zh) * | 2018-04-05 | 2024-05-01 | 美商奇諾治療有限公司 | T細胞受體及表現其之工程化細胞 |
| EP3775237A1 (en) * | 2018-04-05 | 2021-02-17 | Juno Therapeutics, Inc. | T cells expressing a recombinant receptor, related polynucleotides and methods |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| WO2020030631A1 (en) * | 2018-08-06 | 2020-02-13 | Medigene Immunotherapies Gmbh | Ha-1 specific t cell receptors and their use |
| JP7558151B2 (ja) * | 2018-09-05 | 2024-09-30 | アダプティミューン・リミテッド | Ｔ細胞改変 |
| JP7393752B2 (ja) * | 2018-10-05 | 2023-12-07 | 株式会社癌免疫研究所 | 良性腫瘍の予防または治療薬 |
| AU2019362879B2 (en) | 2018-10-16 | 2026-02-19 | Intellia Therapeutics, Inc. | Compositions and methods for immunotherapy |
| GB201817821D0 (en) * | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
| BR112021017703A8 (pt) | 2019-03-11 | 2023-04-18 | Hutchinson Fred Cancer Res | Receptores de células t wt1 de alta avidez e usos dos mesmos |
| CN111714618B (zh) * | 2019-03-22 | 2024-07-12 | 香雪生命科学技术（广东）有限公司 | T细胞和高亲和力pd-1融合蛋白的组合 |
| EP3750547A1 (en) * | 2019-06-13 | 2020-12-16 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Modified nk-92 cells, and therapeutic and diagnostic uses thereof |
| US20220409661A1 (en) * | 2019-08-20 | 2022-12-29 | Fred Hutchinson Cancer Research Center | T-cell immunotherapy specific for wt-1 |
| WO2021135178A1 (zh) * | 2019-12-30 | 2021-07-08 | 华夏英泰（北京）生物技术有限公司 | 一种增强型t细胞受体star及其应用 |
| CN114106144B (zh) * | 2020-08-27 | 2024-01-26 | 溧阳瑅赛生物医药有限公司 | 识别hla-a*02/wt1靶点的tcr及其应用 |
| US20250032540A1 (en) | 2020-12-14 | 2025-01-30 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| KR20240026898A (ko) * | 2021-04-21 | 2024-02-29 | 옥스포드 유니버시티 이노베이션 리미티드 | 방법 및 조성물 |
| US20240238341A1 (en) * | 2021-05-20 | 2024-07-18 | Washington University | Neuroprotective compositions and methods |
| KR20240034234A (ko) | 2021-07-14 | 2024-03-13 | 2세븐티 바이오, 인코포레이티드 | 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체 |
| CN113773378B (zh) * | 2021-10-14 | 2023-11-03 | 深圳大学总医院 | T细胞受体及其应用 |
| US20240390423A1 (en) * | 2021-10-29 | 2024-11-28 | Yafei Hou | T cell receptor recognizing s37f mutation in ctnnb1 and its application |
| CN119546327A (zh) | 2022-04-08 | 2025-02-28 | 再生元制药公司 | 多部分受体和信号传导复合物 |
| TW202417476A (zh) | 2022-08-18 | 2024-05-01 | 英商英美偌科有限公司 | Ｔ細胞受體及其融合蛋白 |
| WO2024092265A2 (en) * | 2022-10-28 | 2024-05-02 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ewsr1-wt1 fusion protein and uses thereof |
| WO2024178397A2 (en) | 2023-02-24 | 2024-08-29 | Elevatebio Technologies, Inc. | Modified immune effector cells and methods of use |
| CN121712794A (zh) | 2023-06-29 | 2026-03-20 | 迪斯派奇生物治疗公司 | 合成细胞因子受体 |
| WO2025240518A1 (en) | 2024-05-14 | 2025-11-20 | Dispatch Biotherapeutics, Inc. | Modified lentiviral transfer plasmids |
| GB202406990D0 (en) * | 2024-05-16 | 2024-07-03 | Univ Oxford Innovation Ltd | T cell receptors and uses thereof |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
| WO2026006767A1 (en) | 2024-06-28 | 2026-01-02 | Dispatch Biotherapeutics, Inc. | Tethered il-9/il-9r and related engineered cells and methods |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| EP1103564B1 (en) | 1998-07-31 | 2009-01-07 | International Institute of Cancer Immunology, Inc. | Cancer antigens based on tumor suppressor gene wt1 product |
| GB9823897D0 (en) | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| ES2538486T3 (es) | 2002-09-12 | 2015-06-22 | International Institute Of Cancer Immunology, Inc. | Preparación de péptidos antigénicos contra el cáncer |
| US7575925B2 (en) | 2002-12-10 | 2009-08-18 | Sunnybrook Health Sciences Centre | Cell preparations comprising cells of the T cell lineage and methods of making and using them |
| ES2556232T3 (es) | 2004-03-31 | 2016-01-14 | International Institute Of Cancer Immunology, Inc. | Péptidos antigénicos del cáncer derivados de WT1 |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| CA2743669C (en) | 2008-11-24 | 2018-10-16 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | High affinity t cell receptor and use thereof |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| BR112013006718B1 (pt) | 2010-09-20 | 2021-12-07 | Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh | Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo |
| US9751928B2 (en) * | 2012-05-03 | 2017-09-05 | Fred Hutchinson Cancer Research Center | Enhanced affinity T cell receptors and methods for making the same |
| CN104684926B (zh) | 2012-07-27 | 2022-04-08 | 伊利诺伊州大学理事会 | 工程化t细胞受体 |
| US10377808B2 (en) * | 2013-01-29 | 2019-08-13 | Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Berlin-Buch | High avidity antigen recognizing constructs |
-
2015
- 2015-07-30 WO PCT/US2015/042986 patent/WO2016022400A1/en not_active Ceased
- 2015-07-30 JP JP2017505792A patent/JP6712261B2/ja not_active Expired - Fee Related
- 2015-07-30 ES ES15753531T patent/ES2841274T3/es active Active
- 2015-07-30 CA CA2956545A patent/CA2956545A1/en active Pending
- 2015-07-30 CN CN201580049647.6A patent/CN107074970B/zh active Active
- 2015-07-30 US US14/813,782 patent/US10538572B2/en active Active
- 2015-07-30 EP EP15753531.1A patent/EP3177314B1/en active Active
-
2018
- 2018-07-30 JP JP2018142600A patent/JP2018183175A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523784A5 (enExample) | ||
| JP7157839B2 (ja) | 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ | |
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| Johdi et al. | Colorectal cancer immunotherapy: options and strategies | |
| JP7223055B2 (ja) | 癌治療のための併用免疫療法及びサイトカイン制御療法 | |
| Baxevanis et al. | Cancer immunotherapy | |
| Dotti et al. | Design and development of therapies using chimeric antigen receptor‐expressing T cells | |
| Di et al. | Combined adjuvant of poly I: C improves antitumor effects of CAR-T cells | |
| Zeltsman et al. | CAR T-cell therapy for lung cancer and malignant pleural mesothelioma | |
| Redeker et al. | Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination | |
| JP2020509767A5 (enExample) | ||
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| Bernatchez et al. | Advances in the treatment of metastatic melanoma: adoptive T-cell therapy | |
| JP2016520074A5 (enExample) | ||
| JP2017531687A5 (enExample) | ||
| WO2018193119A1 (en) | Gene therapy | |
| WO2017159736A1 (ja) | 免疫機能制御因子を発現する免疫担当細胞及び発現ベクター | |
| JP2020533962A5 (enExample) | ||
| Zhang et al. | Genetic engineering with T cell receptors | |
| Danhof et al. | CARs and other T cell therapies for MM: the clinical experience | |
| Dhodapkar et al. | Hematologic malignancies: plasma cell disorders | |
| Brayer et al. | Developing strategies in the immunotherapy of leukemias | |
| Garber et al. | Adoptive T-cell therapy for Leukemia | |
| KR20220087431A (ko) | T 세포 수용체 및 이의 사용 방법 | |
| Hanagiri et al. | Retracted: Antitumor activity of human γδ T cells transducted with CD 8 and with T‐cell receptors of tumor‐specific cytotoxic T lymphocytes |